At a Glance Commentary. Scientific Knowledge on the Subject: New therapies for severe asthma, particularly treatments that reduce exacerbation, remain a significant unmet medical need. Development of human relevant preclinical models are needed to further elucidate the complex mechanisms underlying asthma exacerbation and investigate new therapeutic strategies. What This Study Adds to the Field: Using a human Airway Lung-Chip model, we show here for the first time a live human rhinovirus (HRV) infection of the asthmatic epithelium that recapitulates complex clinical features of viral-induced asthma exacerbation. The dynamic microenvironment of the chip enables the real-time study of virus infection, epithelial response, and immune cell recruitment under healthy and asthmatic conditions. The model reproduces key endpoints that have been observed in asthmatics and individuals infected with rhinovirus including the ciliated cell sloughing, altered cilia beating frequency, goblet cells hyperplasia, increased expression of adhesion molecules in microvascular endothelial cells, and inflammatory mediator release. High-resolution temporal analysis of secreted inflammatory markers enabled by dynamic sampling revealed alteration of IL-6, IFN-λ1 and CXCL10 secretory phases after rhinovirus infection in an IL-13 high environment. Leveraging high-content imaging and analysis of circulating inflammatory cells, we demonstrated the efficacy of a CXCR2 antagonist to reduce adhesion, motility, and transmigration of perfused human neutrophils. Thus, this microengineered chip may offer a powerful addition to preclinical models for understanding mechanisms underlying asthma exacerbation pathology and developing new therapeutic strategies. Abstract Rationale: Viral-induced exacerbation of asthma are a major cause of hospitalization and mortality. Our understanding of the complex mechanisms underlying asthma exacerbation is hindered by the lack of physiological relevance and cellular complexity of traditional in vitro systems and the limited human translatability of animal models. Objectives: To develop a new micro-engineered model of rhinovirus-induced asthma exacerbation that recapitulates live viral infection of asthmatic airway epithelium, neutrophil transepithelial migration, and enables evaluation of immunomodulatory therapy. Methods: A micro-engineered model of fully differentiated human mucociliary airway epithelium was stimulated with IL-13 to induce a Th2-type asthmatic phenotype and infected with live human rhinovirus 16 (HRV16) to reproduce clinical features of viralinduced asthma exacerbation. Measurements and Main Results: Infection with HRV16 replicated key hallmarks of the cytopathology and inflammatory responses observed in human airways. Generation of a Th2 microenvironment through exogenous IL-13 stimulation induced features of asthmatics airways, including goblet cell hyperplasia, reduction of cilia beating frequency, and endothelial activation, but did not alter rhinovirus infectivity or replication. High resolution kinetic analysis of secreted inflammatory markers revealed that IL-13 treatment altered the IL-6, IFN-λ1, and CXCL10 secretory phases in response to HRV16. Airway Lung-Chips perfused with human neutrophils demonstrated greatest neutrophil transepithelial migration when viral infection was combined with IL-13 treatment, while treatment with MK-7123, a CXCR2 antagonist, reduced neutrophil diapedesis in all conditions.
Introduction.
Asthma is a highly prevalent chronic inflammatory disease of the respiratory tract defined by shortness of breath, wheezing, and chest tightness that affects 300 million people worldwide (1) . While significant therapeutic progress has been made in managing asthma with inhaled corticosteroids and bronchodilator medication, 5-10% of patients suffer from so-called severe asthma where the disease remains uncontrolled despite high-dose treatment, often resulting in exacerbation (2) . Asthma exacerbations are characterized by acute episodes of worsening asthma symptoms and decreased lung function that can lead to emergency hospitalizations and death. Indeed, the majority of morbidity, mortality and economic costs associated with asthma in developed countries derives from acute care for asthma exacerbations (3, 4) . Prevention and treatment of severe asthma attacks hence remains an area of considerable unmet medical need (5) . New human-relevant models that reproduce key aspects of the human physiology, function, and immune responses of the airways during exacerbation are critically needed in order to advance development of new therapeutics (6) .
Organs-on-chips offer the opportunity to generate physiologically relevant models of human tissue that recapitulate the multicellular architecture, tissue-tissue interfaces, physiochemical microenvironement (including mechanical forces such as shear stress), and vascular perfusion of the body (7) . Here, we have used an advanced microengineered Airway Lung-Chip that recapitulates the structure and function of a welldifferentiated human mucociliary airway epithelium and its interaction with a continuously perfused microvascular pulmonary endothelium under physiological, in vivo-like haemodynamic shear stress (8) and applied it to generate a model of rhinovirus-induced asthma exacerbation. Respiratory viral infections are believed to be a key trigger for exacerbations in children and adults, with human rhinovirus (HRV), a ubiquitous viral pathogen responsible for the common cold, being the most common infectious agent associated with exacerbations (9) . Respiratory viral infections trigger asthma exacerbation through several mechanisms, including airway inflammation, mucus hypersecretion, and bronchial hyperresponsiveness. Studies have also revealed association between impaired immune responses and asthma exacerbation during viral infection (10, 11) . The Airway Lung-Chip not only recapitulates many of these effects, but, in conjunction with innovative high-content imaging and microfluidic sampling strategies, it also provides new insights into how the asthmatic Th2 microenvironment derails the host immune responses. In addition, by allowing for the real-time evaluation of immune cell dynamics, the Airway Lung-Chip provides a novel platform for testing immunomodulatory therapeutics for the treatment and prevention of viral-induced asthma exacerbation.
Methods.
Complete methods can be found in the online supplement.
Cell differentiation and rhinovirus infection on-chip.
Cells were cultured and differentiated as previously described (8) . Briefly, hAECs were seeded in the Airway Lung-Chips on a human placenta collagen IV-coated 3-µm pore polyester membrane at a density of 3 x 10 6 cells/mL and left to attach for 2h. Five days post seeding, air liquid interface (ALI) was introduced and Airway Lung-Chips were perfused basally at 60µL/h for 3 weeks until full differentiation. Epithelium integrity, ciliation, and apical mucus secretion were monitored for quality control. When complete epithelial differentiation was reached, hMVECs or HUVECs were seeded onto the opposite side of the membrane, in the vascular channel at a density of 1 x 10 7 cells/mL and cultured under flow for 3-4 days in endothelial growth media (EGM2-MV, Lonza, USA 
Results.

Generation of an on-chip model of the human airways that enables immune cell transmigration.
We developed a Lung Airway Lung-Chip suitable for the study of viral-induced asthma exacerbation and the effect of immunomodulatory compounds on immune cell dynamics.
Here, we adapted our recently developed micro-engineered "small-airway-on-a-chip" model (8) and engineered a new chip design containing a membrane with increased pore size (3.0 µm vs 0.4 µm) to allow immune cells to transmigrate from the vascular microchannel to the epithelial lumen and thus replicate inflammatory infiltrates observed in exacerbations ( Fig. 1a) . To validate the new membrane configuration, human primary airway epithelial cells (hAECs) were cultured and differentiated at air liquid interface (ALI) for 21 days on top of the collagen-coated 3-µm pore membrane while differentiation medium was continuously perfused at 60 µL/h through the bottom channel. Human primary endothelial cells were then seeded on the opposite side of the membrane and cultured under similar flow rate until they became confluent to create a tissue-tissue interface ( Fig. 1a) .
Establishment of a well-differentiated mucociliary bronchiolar epithelium on one side of the 3-µm pore membrane and a confluent pulmonary microvascular endothelium on the opposite side was confirmed by immunofluorescence ( Fig. 1 b-f ). Robust Zo-1-containing tight junctions outlined a characteristic epithelial cobblestone-like morphology ( Fig. 1b) .
MUC5AC staining revealed that ca. 18% of cell were mucus producing goblet cells and and β-tubulin staining identified ca. 30% of cells to be ciliated ( Fig. 1c, d) , which are proportions consistent with ranges found in normal human airways (12) . Immunostaining for the endothelial junctional protein VE-Cadherin showed the formation of an intact, continuous microvascular endothelium opposed to the epithelium (Fig. 1e) . Using highspeed, real-time microscopy, we found that cilia were actively beating in a synchronized fashion at a frequency of 16.35 (± 2.6) Hz ( Fig. 1f, g, Supplementary movie 1) , generating a locally unidirectional mucociliary transport visualized by recorded trajectories of rapidly moving fluorescent microbeads diluted in PBS and introduced in the top channel ( Fig. 1h ) as well as tumbling small plugs of cell debris trapped in mucus (Supplementary movie 2). The measured bead velocity was typically ~ 100 µm/sec, which is strikingly close to the values estimated for intact human airways (13) . Thus, the Airway Lung-Chip recapitulated key fundamental structural and functional parameters of normal human bronchioles suitable to investigate immune cells transmigration through its 3-µm pore membrane.
HRV16 readily infects the Airway Lung-Chip and induces cytopathic effects.
We next asked whether the Airway Lung-Chip model could also support infection of live respiratory virus and reproduce features of the cytopathic response observed in vivo. As human rhinovirus (HRV) is the pathogen most commonly associated with asthma exacerbation in adult and children (9, 14) , we infected the chip with HRV16, a rhinovirus serotype commonly used in clinical challenge studies, and analyzed viral infectivity and replication, cell tropism and induced cytopathic effects (CPE). Infection of the chips with HRV16 at a multiplicity of infection (MOI) of 1 resulted in a rapid apical release of infectious virus particles that peaked between 24 and 48 hours post infection (hpi) followed by a steady decline of released virions until no virus was detected 144 hpi ( Fig.   2a ), this timeframe was consistent with viral shedding and symptom score profiles of individuals experimentally infected with HRV (15) (16) (17) .
HRV16 readily infected the intact epithelium and induced significant apical cell sloughing by 24 hpi (Fig. 2b) , indicative of a robust infection. Real time imaging and immunofluorescence characterization identified that the majority of detached cells were infected multiciliated cells ( Fig. 2c, Supplementary movie 3) , similar to what has been observed in respiratory tissue biopsies of human volunteers experimentally infected with HRV (18, 19) . Many of the detached cells were TUNEL-positive, indicating apoptosis ( Fig.   2d ). Immunofluorescence confocal microscopic analysis of infected chips revealed that HRV16 infection was restricted to ciliated cells and induced infected cells protrusion and extrusion from the epithelial lining, while mucus producing cells remained non-infected ( Fig.2 e, Supplementary movie 3) . By day 6 post infection, the majority of ciliated cells had disappeared from the epithelial surface (13 fold decrease cilia coverage; p<0.001) ( Fig. 2f, g) while the few remaining ciliated cells displayed significantly shorter cilia ( Fig.   2f , Supplementary Fig. 1 ). Interestingly, we found that not every ciliated cell was infected at 24 hpi, suggesting that several rounds of infection might occur during the course of infection. Additionally, consistent with HRV16 ciliated cells tropism, we observed a 60% reduction in cilia beating frequency following infection (p<0.001) ( Fig. 2h and Supplementary movie 4). Furthermore, acute damage to ciliated cells was accompanied by a substantial epithelial remodeling characterized by a 2 x increase in the area covered by MUC5AC positive cells by 6 days post infection compared to non-infected control chips (p<0.001) ( Fig. 2i, j) , in line with previous clinical observation of human subjects infected with HRV (20) .
Modeling features of viral-induced asthma exacerbation on-chip.
To recapitulate HRV-induced asthma exacerbation in the Airway Lung-Chip and study the underlying mechanisms of the disease, we used interleukin-13 (IL-13) stimulation to induce features of Type 2 inflammation in asthma and combined this treatment with HRV16 infection to induce exacerbation ( Fig. 3a) . IL-13 plays a central role in allergic asthma and, together with IL-5, is an important mediator of viral-induced exacerbations in asthma (21) . When we treated the Airway Lung-Chip with IL-13 (100 ng/mL) for 7 days preceding virus infection, we detected a significant increase in the number of goblet cells (rising from 16.5% to 50.3% total area; p<0.01) ( Fig. 3b, c) and a decrease in cilia beating frequency (14.4% reduction; p<0.001) ( Fig. 3d, e and Supplementary movie 5), which is consistent with observations made in airway mucosa of asthmatic patients (22, 23) .
When we infected the IL-13 treated Airway Lung-Chip with HRV16, we did not detect significant changes in viral loads in apical washes nor in the duration of infection when compared with non-stimulated chips (Fig. 3f ). This finding was consistent with recent studies in adults and children asthmatics experimentally infected with HRV16 (24) (25) (26) .
Type 2 inflammation has been suggested to increase asthmatics susceptibility to exacerbations through airway remodeling and modulation of the antiviral response (27) .
To gain insight into the effect of IL-13 on HRV16-induced inflammatory response we first measured the levels of pro-inflammatory cytokines and chemokines released apically and basolaterally at 24, 48 and 72 h post HRV16 infection, in the presence or absence of IL-13 ( Fig.4a-c and Supplementary Fig. 2 ). Apical and basolateral secretion of CCL11, a potent eosinophil chemoattractant and markers of Th2 asthma in human (28) , was increased following HRV16 infection ( Fig. 4a) . This was not significantly altered by IL-13 treatment. In contrast, apical secretion of CCL26, another chemokine associated with eosinophils recruitment and persistence in patients with asthma (29) , was increased at all time points following stimulation with IL-13 alone, while HRV16 infection had no effect on CCL26 release. Analysis of the interferon (IFN) type III response revealed that apical and basal release of IFN-λ1 at 48 hpi, and of IFN-induced lymphocytes chemoattractant CXCL10 at 48 and 72 hpi were increased following HRV16 infection ( Fig. 4b) . Markedly, IL-13 treatment significantly reduced measured IFN response in HRV16 infected chips, consistent with clinical reports showing that individuals with asthma or cells from asthmatics infected with HRV have a deficient IFN response (30, 31) , and supporting the idea that asthmatics have an impaired immune response to viral infections (11) .
Furthermore, quantification of pro-inflammatory cytokines and chemokines associated with asthma exacerbations in vivo revealed increased IL-8 basal secretion 48 h post HRV16 infection and this was not significantly altered by IL-13 treatment (Fig. 4c) . In contrast, we found that induction of IL-6 apical and basal secretion following HRV16 infection was greatly reduced in IL-13 treated samples at 48 h post infection ( Fig. 4c) .
Indeed, other studies have also found an altered cytokine expression in asthmatic airways in response to injury, potentially due to an altered proportion of basal cells relative to ciliated and goblet cells (32) . Notably, we did not detect any IFN-β secretion at any time point with and without IL-13 stimulation.
While measuring the level of secreted inflammatory mediators is essential to understand the nature and magnitude of the inflammatory response during exacerbation events, the kinetic profile of cytokines secretion is equally important to identify the distinct phases of the pathophysiological process and investigate the mechanisms underlying the resolution of inflammation (33, 34) . To further elucidate the kinetics of inflammatory mediators release during viral-induced asthma exacerbations, we then leveraged the microperfusion of the Airway Lung-Chip for high resolution temporal profiling of IFN-λ1, CXCL10 and IL-6 secretion. By collecting basal medium flow-through every 2 h for 74h, we determined a temporal signature of IFN-λ1, CXCL10 and IL-6 secretory pattern, and identify distinct secretion phases ( Fig. 4d) . We found that IFN-λ1 increased exponentially until a peak at When we stimulated the Airway Lung-Chip through the vascular compartment with IL-13
(100 ng/mL) for 48 h, we observed progressive endothelium morphological changes leading to the formation of cell aggregates throughout the vascular wall ( Fig. 5a) accompanied by a 2 x increased endothelial cell density (p < 0.0001) ( Fig. 5b) . These morphological changes are in line with previous studies that indicate an involvement of the Interleukin-4 receptor (IL-4R) alpha chain (CD124) (35) . Analysis of genes expressed by endothelial cells cultured alone or under IL-13 stimulation (100 ng/mL) for 48 h showed upregulation of P-Selectin (p = 0.036) and E-Selectin (p = 0.06), two adhesion molecules involved in inflammatory cell recruitment ( Fig. 5c, Supplementary Table 2 ).
Fluorescence intensity of stained intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion protein 1 (VCAM-1) was also significantly increased in IL-13 treated cultures compared to untreated control ( Fig. 5d, Supplementary Fig. 3 ), supporting an active contribution of IL-13 to the inflammatory response and infiltration of immune cells through activation of the lung microvascular endothelium, in line with previous study showing increased adhesion molecules expression on endothelial cells in bronchial biopsies from subjects with asthma (36) .
Pharmacological modulation of neutrophil recruitment and transmigration by a CXCR2 antagonist on-chip.
While asthma is commonly associated with eosinophilia, neutrophils are the predominant cell type recovered from sputum during early stages of an acute asthma exacerbation (37) . When we perfused freshly isolated human neutrophils stained with a live dye through the lower channel of severe asthma chips under physiological flow and shear stress (1 dyn/cm 2 ), we observed neutrophil adhesion and crawling at the surface of the microvascular endothelium, rapidly followed by neutrophil transendothelial migration through a combination of transcellular and paracellular migratory events ( Fig. 6a, b) .
Treatment with IL-13 and HRV16, alone or in combination significantly increased neutrophil adhesion ( Fig. 6c, d) . Treatment with 10 µM MK-7123, a CXCR2 antagonist, at 24 hpi significantly reduced neutrophil adhesion to the endothelium induced by IL-13
and HRV16 alone or in combination by > 75% when compared with non-treated conditions ( Fig. 6c, d) . This response was accompanied by a reduction in neutrophil velocity (Fig.   6e, f and Supplementary movies 6 and 7) . We also observed a significant twofold increase in neutrophil recruited between HRV infected chips and infected chips in presence of IL-13 (953 vs 1999; p < 0.001) ( Fig. 6d) .
Real time fluorescence imaging of circulating human neutrophils revealed that many endothelium bound neutrophils transmigrated from the vascular channel through the 3µm pores of the membrane (which frequently merge into even larger pores in these tracketched membranes) into the epithelium channel where they adhered to the epithelial surface ( Fig. 6g and Supplementary movie 8) and treatment with MK-7123 reduced the proportion of transmigrating neutrophils (Fig. 6h) . Furthermore, characterization of fully migrated neutrophils revealed expression of myeloperoxidase (Fig. 6i) , a marker of neutrophil activation found in lungs of asthmatics (38) that contributes to inflammation in vivo (39) . Thus, our on-chip disease model of asthma exacerbation not only enabled testing for the efficacy of an anti-inflammatory compound but also allowed further elucidation of the multi-step dynamics of neutrophil recruitment in a human-relevant context with the potential for clinical translation.
Discussion
We still incompletely understand why asthmatics are at higher risk of developing lifethreatening exacerbation following rhinovirus infection. Previous in vitro studies have suggested that damage to the asthmatic airway epithelium induced by allergens or pollutants facilitates HRV infection by exposing more permissive, ICAM-1-expressing basal cells, explaining the inability of the asthmatic airway epithelium to effectively protect the lung from infection (40, 41) . The corollary is the perception that intact epithelial layers of healthy subjects are somewhat resistant to HRV infection, implying that HRV is generally non-cytopathic and unable to cause substantial damage to the epithelium (42) .
Contrasting with this view, our findings demonstrate that HRV can readily infect the intact well-differentiated mucociliary epithelium on-chip and induce significant airway Recognizing the central role of IL-13-induced epithelium remodeling in allergic asthma, several groups have investigated the effect of IL-13-induced mucous metaplasia on the susceptibility of human airway epithelium to HRV infection (41, 43, 44) . The studies, however, have reported discordant findings. While one study showed that IL-13-induced mucous metaplasia increased susceptibility to HRV infection (44) , another one showed a reduced susceptibility of the airway epithelium to HRV infection (43) . In contrast, we did not detect any significant difference in viral load or infection persistence in IL-13 treated chips compared with non-treated controls. Difference in epithelial cells origin (tracheobronchial vs small airway), donor to donor variability, specific culture conditions (static vs dynamic) and/or infection protocols (incubation temperature and MOI) might explain the differences between previous reports and our data. However, our observations are supported by several recent clinical studies investigating viral load in asthmatics and non-asthmatics infected with HRV (24) (25) (26) 45) . Consistent with our results, these studies showed no difference in viral titer in both the upper and lower respiratory tracts of asthmatic and non-asthmatic, adults and children, infected with HRV.
These studies serve to validate our findings and confirm the clinical relevance of the Airway Lung-Chip in modeling viral-induced asthma exacerbation.
Rather than an intrinsic susceptibility of asthmatics lungs to HRV infection, past studies have found that hAECs of asthmatics cultured in vitro displayed a deficient innate immunity to HRV infection (11, 30, 31) . We found that HRV-induced type III IFN response was ablated in a type 2 microenvironment, and these results were consistent with clinical studies showing impaired IFN response in asthmatic individuals challenged with HRV (30, 46) . However, several recent in vitro and in vivo studies have reported no difference in IFN signatures between asthmatics and non-asthmatic cells or individuals (24, 26, 47, 48) , demonstrating that HRV infections are often well controlled in asthmatics and suggesting that an impaired IFN responses may not be the only contributing factor to initiate an exacerbation. These conflicting findings may be a consequence of asthma phenotype heterogeneity. It is possible that a deficient IFN response to HRV infection constitutes a distinct subset of asthma patients. In fact, an increased susceptibility to exacerbations through an impaired IFN response might be specific to asthmatics with a Th2-dominant inflammatory profile as studies and clinical trials for Th2 directed therapies seem to suggest (21, 30) , in line with our findings demonstrating the downregulation of IFN-λ1 by a Th2 microenvironment on chip.
Orchestration and resolution of the immune cell and tissue response relies on both magnitude and kinetics of secreted cytokines and chemokines. The pleiotropic inflammatory cytokine IL-6 is a prime example as its pro-or anti-inflammatory nature greatly depends on its secretion timing (34) . Here, we have leveraged the microscale perfusion of the Airway Lung-Chip to conduct high resolution profiling and reveal the release kinetics of inflammatory mediators. We found that IL-6 secretory phases are markedly disrupted by IL-13 stimulation. This could be due to the altered epithelial cell type composition of the asthmatic microenvironment, which, as we also show, induces goblet cell hyperplasia and other architectural changes (49) . The central role of IL-6 in infection and inflammation has been extensively described (50) and its protective role was highlighted in several studies. For instance, IL-6 has been shown to limit inflammation, promote protective adaptive immune response, and prevent fatal lung immunopathology induced by influenza virus infection (51) . IL-6 also plays a role in the resolution of innate immunity by contributing to the transition from the recruitment of neutrophils to lymphocytes and monocytes, thus helping prevent excessive tissue damage and promote repair (33) . IL-6 also tempers inflammatory responses by inducing the secretion of anti-inflammatory IL-10 by T cells (52) and IL-6 overexpression in lungs of transgenic mice diminishes airway reactivity to methacholine (53) suggesting a role for IL-6 in airway homeostasis. More recently, a study in asthmatics and OVA sensitized mice infected with HRV showed that blocking of IL-25 receptor resulted in a reduction of the HRV-induced inflammatory response and cytokine expression, with the exception of IL-6, whose secretion increased in recovering animals (54) . Usually considered a proinflammatory mediator in asthma exacerbations, our results and others may suggest a more nuanced role for IL-6 in exacerbation pathogenesis.
One potential limitation of our platform is the incomplete repertoire of resident and immune cells present in asthmatic airways which can respond to the pro-and antiinflammatory cues orchestrating the host immune response. However, a great advantage of our model system is the ability to independently modulate all the system parameters, 
